Senores Pharmaceuticals Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹372 - ₹391
- Lot size
- 38 shares
- Issue amount
- ₹582.11 cr
- Total subscription
- 97.25×
- Opens
- 20 Dec 2024
- Closes
- 24 Dec 2024
- Allotment
- 26 Dec 2024
- Listing
- 30 Dec 2024
Offer at a glance
Issue overview
- Issue size
- 1,48,87,723 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹14,136
- Fresh issue
- ₹500 cr
- Offer for sale
- ₹82.11 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,858
- Issue type
- Bookbuilding IPO
- Shares before issue
- 3,32,65,865
- Shares after issue
- 4,60,53,588
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 1 | 38 | ₹14,858 |
| sHNI | 14 | 532 | ₹2,08,012 |
| bHNI | 68 | 2,584 | ₹10,10,344 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| HNIs (10L+) | 2,644 | 53,198 |
| HNIs(2-10L) | 1,322 | 1,42,233 |
| Retail | 38,982 | 30,76,031 |
| Employee | 0 | 29,405 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| NIB | 86.88 | 8,734.89 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Sep-24 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 7.2 | 13.67 | 8.87 |
| ROE | 8.69 | 23.6 | 20.55 |
| ROCE | 7.59 | 11.73 | 18.56 |
| RONW | 8.69 | 23.6 | 20.55 |
| PRE IPO | 0 | 39.77 | 0 |
| POST IPO | 28.21 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Senores Pharmaceuticals Limited, incorporated on December 26, 2017, is an Ahmedabad-based pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded generic medicines for both domestic and global markets. Its diversified product portfolio spans key therapeutic areas, including gastrointestinal, cardiovascular, respiratory, pain management, and anti-infective segments. Driven by strong R&D capabilities, the company emphasizes innovation, cost-effective product development, and strict regulatory compliance. Senores operates through a robust distribution network supported by subsidiaries such as Ratnatris Pharmaceuticals Private Limited and Havix Group, Inc. (Aavis Pharmaceuticals). It serves customers across major international markets, including the US, Europe, and other emerging regions.
Strengths
- Global Market Presence: Strong footprint across regulated and semi-regulated markets ensures diversified revenue and reduced geographical dependence.
- Robust R&D & Manufacturing: Advanced R&D capabilities enable development of complex generics while adhering to strict global regulatory standards for quality.
- Strategic Partnerships: Long-term relationships with major clients, suppliers, and distributors support steady growth and consistent revenue visibility.
Risk factors
- Regulatory Challenges: Delays or denials in product approvals may hinder new launches and limit growth in key markets.
- Raw Material Volatility: Dependence on external API and raw material suppliers exposes the company to price fluctuations and supply disruptions.
- Intense Competition: A highly competitive pharma landscape may pressure pricing and reduce profit margins.
Promoters
Swapnil Jatinbhai Shah
Ashokkumar Vijaysinh Barot
Registrar & documents
Lead manager
Equirus Capital Private Limited, Ambit Private Limited, Nuvama Wealth Management Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
1101 to 1103, 11th floor,, South Tower, ONE 42 oppositeJayantilal Park, Ambali Bopal Road, Ahmedabad,-380054
+91-79-29999857
[email protected]Company website ↗Understanding SENORES IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.